Want to see VCEL full AI Analyst Report?
VCEL Stock Chart & Stats
$35.68
$1.36(2.35%)
At close: 4:00 PM EST
$35.68
$1.36(2.35%)
Day’s Range― - ―
52-Week Range$28.95 - $46.62
Previous CloseN/A
Volume83.17K
Average Volume (3M)668.69K
Market Cap
$2.27B
Enterprise Value$1.98B
Total Cash (Recent Filing)$145.34M
Total Debt (Recent Filing)$94.54M
Price to Earnings (P/E)102.8
Beta0.88
Next Earnings
Aug 05, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding51,068,230
10 Day Avg. Volume663,036
30 Day Avg. Volume668,686
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)5.14
Price to Sales (P/S)6.59
P/FCF Ratio73.61
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue6.79
Enterprise Value/Gross Profit9.07
Enterprise Value/Ebitda56.25
Forecast
1Y Price Target
$61.00Price Target Upside70.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.47
Revenue Forecast (FY)$332.18M
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow provides durable internal funding for commercial expansion, manufacturing build-out and clinical programs without heavy external financing. Strong cash conversion (OCF above net income and multi-quarter FCF) reduces liquidity risk and supports execution over the next 2–6 months.
High Gross Margins & Revenue TurnaroundA ~75% gross margin profile combined with consistent multi-year revenue growth underpins durable unit economics and pricing power in niche autologous therapies. This structural margin buffer supports reinvestment in sales and R&D while enabling improving profitability as fixed costs scale across the business.
Manufacturing Capacity & International PathwayRegulatory approval of a new commercial manufacturing site expands supply capacity and de-risks bottlenecks tied to patient-specific production. The approved facility also creates a durable pathway for geographic expansion (UK filing/launch), diversifying markets and supporting higher sustainable volumes over time.
Bears Say
BARDA Revenue UncertaintyWhile BARDA provides a meaningful addressable opportunity, the bulk is contingent on future options and timelines. Reliance on optional procurement creates planning uncertainty; materially relying on these contingent dollars for near-term growth or margin targets increases execution and timing risk over the coming quarters.
Operational Dependence On Biopsy-to-ImplantBiopsy-to-implant conversion is a core operational throughput metric: declines would directly cut realized volumes and revenue. Maintaining conversion requires ongoing field execution, patient logistics and payer access; this operational dependency is a structural source of volume volatility if execution or referral patterns slip.
Moderate ROE And Operating LeverageMid-single-digit ROE and only moderate operating/net margins indicate the company has yet to fully convert high gross margins into strong capital returns. This limits capital efficiency and suggests further margin or scale improvements are needed to generate stronger, sustainable shareholder returns over the medium term.
Vericel News
VCEL FAQ
What was Vericel Corporation’s price range in the past 12 months?
Vericel Corporation lowest stock price was $28.95 and its highest was $46.62 in the past 12 months.
What is Vericel Corporation’s market cap?
Vericel Corporation’s market cap is $2.27B.
When is Vericel Corporation’s upcoming earnings report date?
Vericel Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 35 days.
How were Vericel Corporation’s earnings last quarter?
Vericel Corporation released its earnings results on May 07, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.153 by $0.033.
Is Vericel Corporation overvalued?
According to Wall Street analysts Vericel Corporation’s price is currently Undervalued.
Does Vericel Corporation pay dividends?
Vericel Corporation does not currently pay dividends.
What is Vericel Corporation’s EPS estimate?
Vericel Corporation’s EPS estimate is -0.03.
How many shares outstanding does Vericel Corporation have?
Vericel Corporation has 51,068,230 shares outstanding.
What happened to Vericel Corporation’s price movement after its last earnings report?
Vericel Corporation reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.153. Following the earnings report the stock price went down -4.486%.
Which hedge fund is a major shareholder of Vericel Corporation?
Currently, no hedge funds are holding shares in VCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.00 (70.96% Upside)
$61.00 (70.96% Upside)
Blogger Sentiment
Neutral
VCEL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $327.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.00%
12-Months-Change
Fundamentals
Return on Equity
6.41%
Trailing 12-Months
Asset Growth
14.38%
Trailing 12-Months
Company Description
Vericel Corporation
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial quarter: record revenue, double-digit MACI growth, materially improved margins, robust cash generation, successful sales force expansion, regulatory and manufacturing milestones, and a meaningful BARDA award. The key near-term risks are timing and contingent nature of BARDA-related revenue, the need to sustain biopsy-to-implant conversion, modest near-term margin variability due to investments, and external macro/access uncertainties. On balance, the positives substantially outweigh the challenges.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$61.00
▲(70.96% Upside)
Technical Analysis
Ownership Overview
1.20% Insiders
28.83% Mutual Funds
45.50% Other Institutional Investors
0.39% Public Companies and
Individual Investors